EYPT Q1 2023 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q1 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-17.3% YoY

Gross Profit

$7M91.7% margin

Operating Income

-$22M-280.5% margin

Net Income

-$21M-275.5% margin

EPS (Diluted)

$-0.58

QoQ Revenue Growth

-27.1%

Cash Flow

Operating Cash Flow

-$17M

Free Cash Flow

-$17M

Stock-Based Comp.

$3M

Balance Sheet

Total Assets

$155M

Total Liabilities

$76M

Stockholders' Equity

$78M

Cash & Equivalents

$106M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$9M	-17.3%
Gross Profit	$7M	$8M	-6.3%
Operating Income	-$22M	-$18M	-17.9%
Net Income	-$21M	-$21M	-0.9%

Revenue Segments

Product

$7M96%

Royalty

$255,0003%

License And Collaboration Agreement

$34,0000%